Study S001140

Comparative Adipose Tissue and Cardiometabolic System Remodeling by Tirzepatide and Semaglutide: an AI-integrated Multimodal Metabolomics and Translational Mechanistic Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07589322
Acronym: COMPARE-AT
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: NONE
Status: RECRUITING
Enrollment: 120
Start: 2026-03-31
Primary completion: 2028-09-30
Lead sponsor: Tri-Service General Hospital (TSGH)
Conditions: Obesity and Metabolic Syndrome
Interventions: DRUG:Tirzepatide with lifestyle modification; DRUG:Semaglutide with lifestyle modification
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Percent change in total body weight from baseline to 6 months. [Baseline to 6 months]
Total fat to lean mass loss ratio (DXA derived) from baseline to 6 months. [Baseline to 6 months]
Change in metabolic syndrome severity Z score from baseline to 6 months. [Baseline to 6 months.]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.